Frankfurt, January 29, 2025. The Hessian state government convened today for an external cabinet meeting at BioSpring in Frankfurt am Main. The main topic of the meeting was the resolution on the Hessen Fund, which aims to drive the transformation and innovation of the Hessian economy with a budget of one billion euros. During a guided tour, BioSpring also provided insights into its high-tech production and analysis of pioneering gene-based therapeutics.
BioSpring is a globally leading manufacturer of active ingredients based on synthetic nucleic acids, supplying multinational biotech and pharmaceutical companies. The company is the world market leader in producing molecules used in genome editing. Genome editing precisely corrects genetic defects and has the potential to fully cure genetically caused diseases with a single treatment—unlike conventional therapies, which only address symptoms.
"Companies like BioSpring are true job engines. They create well-paid jobs and attract other innovative businesses to their surroundings. The company is rightly one of our 'Hessen Champions.' Germany needs more pioneers like BioSpring, whose innovations drive our country forward. That is why the Hessian state government actively supports local businesses through our Hessen Fund and continuously reduces bureaucratic hurdles," said Minister President Boris Rhein.
"BioSpring exemplifies what innovation from Hessen can look like. With their production of novel and highly effective pharmaceuticals, they represent the future industry of medical biotechnology. I am pleased that we can further support such companies and their innovative strength through the Hessen Fund," said Minister of Economic Affairs Kaweh Mansoori.
"Framework conditions such as tax burdens and bureaucracy pose enormous challenges and weaken high-tech companies competing internationally. We are convinced that by removing these obstacles, Hesse will continue to offer enormous potential in the future. It is even more gratifying that the Hessian state government is addressing these challenges with a Ministry for Bureaucratic Reduction and the establishment of the Hessen Fund. This is an important step for Hessen as a business location. Furthermore, we see today's cabinet meeting at our company as another signal to strengthen the Hessian economy and future-oriented industries such as biotechnology," said Dr. Sylvia Wojczewski, CEO of BioSpring.
BioSpring currently produces exclusively in Frankfurt am Main and has created hundreds of new jobs in recent years. Over the coming years, the company plans to expand further and is currently planning the construction of new industrial-scale production facilities in Offenbach am Main. In the long term, up to 1,500 jobs are expected to be created there.
Contact
Dr. Martin Schink, Senior Team Lead Marketing & Communcations
BioSpring Gesellschaft für Biotechnologie mbH
Alt-Fechenheim 34, 60386 Frankfurt am Main
Phone: +49 (0) 69 66055000
Email: schink@biospring.de